Big Pharma: 2012-13′s Flu Vaccine Field

A look at the players that could see a bump this flu season

    View All  
Big Pharma: 2012-13′s Flu Vaccine Field

AstraZeneca

AstraZeneca185 Big Pharma: 2012 13's Flu Vaccine FieldLike Merck, AstraZeneca (NYSE:AZN) doesn’t quite ring a bell as a major influenza play. But, it’s in the game, through its MedImmune subsidiary (which AstraZeneca purchased in 2007).

MedImmune is the maker of the popular FluMist, which is administered as a nasal spray rather than an injection. Sales of FluMist totaled $145 million in the third quarter, and $161 million for all of last year.

As of this writing, James Brumley did not hold a position in any of the aforementioned securities.


Article printed from InvestorPlace Media, http://investorplace.com/2012/12/big-pharma-2012-13s-flu-vaccine-field/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.